| scholarly article | Q13442814 |
| P50 | author | Antonio P Strafella | Q64856164 |
| P2093 | author name string | A Jon Stoessl | |
| Stephane Lehericy | |||
| P2860 | cites work | An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 | Q24599479 |
| Cerebellothalamocortical connectivity regulates penetrance in dystonia | Q24652781 | ||
| The basal ganglia and cerebellum interact in the expression of dystonic movement | Q24653882 | ||
| Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review | Q28272260 | ||
| Emerging concepts in the physiological basis of dystonia | Q28655888 | ||
| Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease | Q29346490 | ||
| Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. | Q30498096 | ||
| Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients | Q33574373 | ||
| Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging | Q33593384 | ||
| Maze training in mice induces MRI-detectable brain shape changes specific to the type of learning | Q33713529 | ||
| Structural, functional and molecular imaging of the brain in primary focal dystonia--a review | Q33829348 | ||
| The basal ganglia communicate with the cerebellum | Q33929203 | ||
| Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease | Q34002057 | ||
| Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease | Q34080479 | ||
| Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease | Q34086449 | ||
| Effects of expectation on placebo-induced dopamine release in Parkinson disease | Q34129314 | ||
| Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor | Q34169409 | ||
| Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study | Q34258327 | ||
| Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system | Q34395267 | ||
| Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease | Q34423750 | ||
| Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent | Q34584062 | ||
| Circuits and circuit disorders of the basal ganglia | Q34599488 | ||
| Individual differences in reward responding explain placebo-induced expectations and effects | Q34653689 | ||
| Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging | Q34708723 | ||
| Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. | Q34801837 | ||
| Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. | Q34836384 | ||
| Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia | Q34986983 | ||
| Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study | Q48115841 | ||
| Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats | Q48192232 | ||
| Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. | Q48290740 | ||
| Progression of cortical thinning in early Parkinson's disease. | Q48308610 | ||
| Functional brain networks in DYT1 dystonia. | Q48389410 | ||
| Primary dystonia: is abnormal functional brain architecture linked to genotype? | Q48439510 | ||
| Digit-specific aberrations in the primary somatosensory cortex in Writer's cramp. | Q48462988 | ||
| Cerebellar modulation of human associative plasticity. | Q48585218 | ||
| Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. | Q48639223 | ||
| Basal ganglia-premotor dysfunction during movement imagination in writer's cramp. | Q48663503 | ||
| Effects of cerebellar TMS on motor cortex of patients with focal dystonia: a preliminary report. | Q48909989 | ||
| Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans. | Q48968618 | ||
| Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. | Q48984065 | ||
| Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. | Q50562845 | ||
| Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. | Q51887913 | ||
| Impairment of the rubber hand illusion in focal hand dystonia. | Q52608769 | ||
| Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. | Q53558839 | ||
| [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. | Q53642827 | ||
| Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia | Q67217660 | ||
| The metabolic topography of idiopathic torsion dystonia | Q70987276 | ||
| Midbrain iron content in early Parkinson disease: a potential biomarker of disease status | Q80437646 | ||
| Dopaminergic network differences in human impulsivity | Q35180321 | ||
| MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. | Q35234522 | ||
| Brain dynamic neurochemical changes in dystonic patients: a magnetic resonance spectroscopy study | Q35542210 | ||
| The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns | Q35564115 | ||
| Metabolic brain networks in translational neurology: concepts and applications | Q36041821 | ||
| Striatal microcircuitry and movement disorders | Q36203205 | ||
| The functional neuroanatomy of dystonia | Q36340491 | ||
| Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study | Q36341411 | ||
| Resting state functional connectivity of the striatum in Parkinson's disease | Q36474693 | ||
| Cerebellar processing of sensory inputs primes motor cortex plasticity | Q36516121 | ||
| Plasticity in gray and white: neuroimaging changes in brain structure during learning | Q36864561 | ||
| The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease | Q36953865 | ||
| Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls | Q37259426 | ||
| Sensory functions in dystonia: insights from behavioral studies | Q37420610 | ||
| Cholinergic dysfunction in Parkinson's disease | Q37709932 | ||
| Molecular pathways in dystonia | Q37816579 | ||
| The cerebellum in Parkinson's disease | Q38081095 | ||
| Amyloid PET Imaging in Lewy body disorders | Q38119776 | ||
| Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism | Q39112644 | ||
| Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography | Q39115872 | ||
| MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study | Q39979236 | ||
| Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. | Q42077769 | ||
| Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? | Q42134434 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration | Q42468187 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy | Q42482808 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias | Q42546203 | ||
| Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures | Q42794711 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants | Q42997555 | ||
| Spatial remapping of cortico-striatal connectivity in Parkinson's disease | Q43285295 | ||
| Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study | Q43290056 | ||
| Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover | Q43549280 | ||
| Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo | Q44641132 | ||
| Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias | Q45030408 | ||
| [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? | Q45090570 | ||
| Microglial activation and dopamine terminal loss in early Parkinson's disease | Q45237159 | ||
| Microglial activation correlates with severity in Huntington disease: a clinical and PET study. | Q45301519 | ||
| Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa | Q45423232 | ||
| Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. | Q45810537 | ||
| Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. | Q46017245 | ||
| A three-dimensional histological atlas of the human basal ganglia. II. Atlas deformation strategy and evaluation in deep brain stimulation for Parkinson disease. | Q47261469 | ||
| P433 | issue | 9942 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 532-544 | |
| P577 | publication date | 2014-06-18 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Imaging insights into basal ganglia function, Parkinson's disease, and dystonia | |
| P478 | volume | 384 |
| Q47722998 | Abnormal Gray Matter Shape, Thickness, and Volume in the Motor Cortico-Subcortical Loop in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Association with Clinical and Motor Features |
| Q39383551 | Acute movement disorders in the medical setting |
| Q48866376 | Alterations of putaminal shape in de novo Parkinson's disease. |
| Q36049945 | Altered activation of protein kinase PKR and enhanced apoptosis in dystonia cells carrying a mutation in PKR activator protein PACT. |
| Q39661805 | Altered striatal circuits underlie characteristic personality traits in Parkinson's disease |
| Q30243899 | An update on the diagnosis and treatment of Parkinson disease |
| Q39151290 | Clinical presentation and management of dyskinetic cerebral palsy. |
| Q38745376 | Comparative assessment of 6-[18 F]fluoro-L-m-tyrosine and 6-[18 F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model |
| Q33363796 | Connectivity Changes in Parkinson's Disease |
| Q64859200 | Corticopallidal Connectome of the Globus Pallidus Externus in Humans: An Exploratory Study of Structural Connectivity Using Probabilistic Diffusion Tractography |
| Q64864808 | Degree of dopaminergic degeneration measured by 99mTc-TRODAT-1 SPECT/CT imaging |
| Q48279155 | Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism |
| Q26776051 | Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias |
| Q41884810 | Evaluating rehabilitation interventions in Parkinson's disease with functional MRI: a promising neuroprotective strategy |
| Q48247496 | F-18 FP-CIT PET in Multiple System Atrophy of the Cerebellar Type: Additional Role in Treatment. |
| Q48452595 | Fluorodopa is a Promising Fluorine-19 MRI Probe for Evaluating Striatal Dopaminergic Function in a Rat Model of Parkinson's Disease. |
| Q36523068 | Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography |
| Q89820446 | Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease |
| Q90462428 | Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling |
| Q91583459 | Longitudinal Changes in Functional Connectivity of the Caudate Is Associated With Recovery From Bell's Palsy |
| Q57794605 | Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs |
| Q36021835 | MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease? |
| Q38695637 | Magnetic resonance imaging as a potential biomarker for Parkinson's disease. |
| Q39220904 | Magnetic resonance imaging for the diagnosis of Parkinson's disease |
| Q64767203 | MiR-410 exerts neuroprotective effects in a cellular model of Parkinson's disease induced by 6-hydroxydopamine via inhibiting the PTEN/AKT/mTOR signaling pathway |
| Q38571789 | Molecular imaging and neural networks in impulse control disorders in Parkinson's disease |
| Q28071336 | Molecular imaging of movement disorders |
| Q64791384 | Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease |
| Q30374657 | Musical training as an alternative and effective method for neuro-education and neuro-rehabilitation. |
| Q64778733 | NADPH Oxidase Mediates Membrane Androgen Receptor-Induced Neurodegeneration. |
| Q57178629 | Network imaging biomarkers: insights and clinical applications in Parkinson's disease |
| Q90717467 | Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy |
| Q48199154 | Neurocognitive outcomes in children with unilateral basal ganglia arterial ischemic stroke and secondary hemidystonia |
| Q31142833 | Neuroinflammation - using big data to inform clinical practice |
| Q37192855 | Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease |
| Q28069529 | Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders |
| Q34163159 | Neuroprotective effect of the traditional Chinese herbal formula Tongxinluo: a PET imaging study in rats |
| Q38658393 | Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues |
| Q99555756 | PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction |
| Q36319286 | Parkinson disease |
| Q30395703 | Post stroke hemi-dystonia in children: a neglected area of research. |
| Q36081612 | Random Forest Classification of Depression Status Based On Subcortical Brain Morphometry Following Electroconvulsive Therapy |
| Q35692168 | Reduced Number of Pigmented Neurons in the Substantia Nigra of Dystonia Patients? Findings from Extensive Neuropathologic, Immunohistochemistry, and Quantitative Analyses |
| Q98157689 | Relative contribution of muscle strength, lean mass, and lower extremity motor function in explaining between-person variance in mobility in older adults |
| Q49601287 | Sex-related differences in oxidative stress and neurodegeneration. |
| Q93190862 | The Aging Brain & the Dorsal Basal Ganglia: Implications for Age-Related Limitations of Mobility |
| Q47629433 | The dopaminergic system dynamic in the time perception: a review of the evidence. |
| Q39208290 | The use of nonhuman primate models to understand processes in Parkinson's disease. |
Search more.